argenx SE (NASDAQ:ARGX) Shares Bought by Fmr LLC

Fmr LLC lifted its stake in argenx SE (NASDAQ:ARGX) by 35.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,793,472 shares of the company’s stock after buying an additional 1,265,486 shares during the period. Fmr LLC owned approximately 0.08% of argenx worth $2,598,445,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of ARGX. J.Safra Asset Management Corp grew its holdings in argenx by 590.0% during the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after purchasing an additional 59 shares in the last quarter. Blue Trust Inc. boosted its position in argenx by 620.0% in the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after buying an additional 62 shares during the last quarter. GAMMA Investing LLC boosted its position in argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after buying an additional 40 shares during the last quarter. Cromwell Holdings LLC grew its stake in shares of argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after acquiring an additional 66 shares in the last quarter. Finally, Point72 Hong Kong Ltd purchased a new stake in shares of argenx during the second quarter worth about $76,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analysts Set New Price Targets

ARGX has been the subject of a number of analyst reports. Scotiabank raised argenx from a “sector perform” rating to a “sector outperform” rating and increased their price target for the company from $439.00 to $715.00 in a report on Tuesday, November 5th. Raymond James reiterated a “strong-buy” rating and set a $605.00 target price on shares of argenx in a research note on Thursday, October 10th. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “buy” rating to a “hold” rating in a research note on Friday, October 4th. HC Wainwright reaffirmed a “buy” rating and issued a $617.00 price target on shares of argenx in a report on Wednesday, November 20th. Finally, Piper Sandler raised their price objective on shares of argenx from $553.00 to $620.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Three research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, argenx has an average rating of “Moderate Buy” and a consensus target price of $630.42.

argenx Trading Down 0.0 %

Shares of NASDAQ ARGX opened at $605.66 on Tuesday. argenx SE has a 12-month low of $327.73 and a 12-month high of $618.40. The company has a market cap of $36.56 billion, a PE ratio of -688.25 and a beta of 0.61. The stock has a 50 day simple moving average of $557.73 and a 200-day simple moving average of $489.55.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. During the same quarter in the prior year, the business posted ($1.25) earnings per share. Sell-side analysts forecast that argenx SE will post 2.2 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.